Tag Archives: AERI

Columbus Circle Investors Raises Position in Aerie Pharmaceuticals (AERI)

Columbus Circle Investors increased its position in shares of Aerie Pharmaceuticals (NASDAQ:AERI) by 6.4% in the 1st quarter, Holdings Channel reports. The firm owned 631,047 shares of the company’s stock after acquiring an additional 37,961 shares during the period. Columbus Circle Investors’ holdings in Aerie Pharmaceuticals were worth $34,234,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of AERI. QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals in the fourth quarter worth $125,000. Public Employees Retirement Association of Colorado acquired a new position in shares of Aerie Pharmaceuticals in the fourth quarter worth $176,000. Bamco Inc. NY raised its holdings in shares of Aerie Pharmaceuticals by 19.4% in the fourth quarter. Bamco Inc. NY now owns 7,351 shares of the company’s stock worth $439,000 after acquiring an additional 1,195 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of Aerie Pharmaceuticals by 47.5% in the third quarter. California Public Employees Retirement System now owns 7,525 shares of the company’s stock worth $366,000 after acquiring an additional 2,425 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Aerie Pharmaceuticals in the fourth quarter worth $617,000. 97.57% of the stock is owned by hedge funds and other institutional investors.

Get Aerie Pharmaceuticals alerts:

A number of research firms have recently weighed in on AERI. Cantor Fitzgerald set a $86.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 8th. Canaccord Genuity set a $86.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. BidaskClub cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 11th. HC Wainwright set a $78.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, Mizuho cut their price target on Aerie Pharmaceuticals to $77.00 and set a “buy” rating for the company in a report on Tuesday, May 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $77.92.

Shares of NASDAQ:AERI opened at $51.15 on Friday. The company has a quick ratio of 13.53, a current ratio of 13.57 and a debt-to-equity ratio of 0.52. Aerie Pharmaceuticals has a 52 week low of $50.38 and a 52 week high of $51.40.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.83) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.04. equities analysts anticipate that Aerie Pharmaceuticals will post -3.75 EPS for the current fiscal year.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $86.00 Price Target

Aerie Pharmaceuticals (NASDAQ:AERI) has been given a $86.00 price target by stock analysts at Canaccord Genuity in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 72.17% from the company’s current price.

AERI has been the subject of a number of other reports. Zacks Investment Research raised Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, January 22nd. Seaport Global Securities initiated coverage on Aerie Pharmaceuticals in a report on Friday, January 26th. They issued a “buy” rating and a $78.00 price target for the company. BidaskClub raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Mizuho reissued a “buy” rating and issued a $87.00 price target on shares of Aerie Pharmaceuticals in a report on Monday, January 29th. Finally, HC Wainwright assumed coverage on Aerie Pharmaceuticals in a report on Friday, February 16th. They issued a “buy” rating and a $78.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $77.92.

Get Aerie Pharmaceuticals alerts:

Shares of NASDAQ:AERI opened at $49.95 on Tuesday. Aerie Pharmaceuticals has a 12-month low of $38.22 and a 12-month high of $66.60. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -14.82 and a beta of 0.96. The company has a debt-to-equity ratio of 0.91, a current ratio of 10.09 and a quick ratio of 10.09.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.04. sell-side analysts anticipate that Aerie Pharmaceuticals will post -3.62 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Bamco Inc. NY raised its stake in shares of Aerie Pharmaceuticals by 19.4% during the 4th quarter. Bamco Inc. NY now owns 7,351 shares of the company’s stock worth $439,000 after buying an additional 1,195 shares during the period. Teachers Retirement System of The State of Kentucky raised its stake in shares of Aerie Pharmaceuticals by 2.1% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 62,720 shares of the company’s stock worth $3,748,000 after buying an additional 1,273 shares during the period. Swiss National Bank raised its stake in shares of Aerie Pharmaceuticals by 2.5% during the 1st quarter. Swiss National Bank now owns 53,900 shares of the company’s stock worth $2,924,000 after buying an additional 1,300 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Aerie Pharmaceuticals by 1.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 108,311 shares of the company’s stock worth $5,876,000 after buying an additional 1,411 shares during the period. Finally, QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth approximately $125,000. 97.32% of the stock is owned by institutional investors and hedge funds.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $86.00 Price Target

Aerie Pharmaceuticals (NASDAQ:AERI) has been given a $86.00 price target by stock analysts at Canaccord Genuity in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 72.17% from the company’s current price.

AERI has been the subject of a number of other reports. Zacks Investment Research raised Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, January 22nd. Seaport Global Securities initiated coverage on Aerie Pharmaceuticals in a report on Friday, January 26th. They issued a “buy” rating and a $78.00 price target for the company. BidaskClub raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Mizuho reissued a “buy” rating and issued a $87.00 price target on shares of Aerie Pharmaceuticals in a report on Monday, January 29th. Finally, HC Wainwright assumed coverage on Aerie Pharmaceuticals in a report on Friday, February 16th. They issued a “buy” rating and a $78.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $77.92.

Get Aerie Pharmaceuticals alerts:

Shares of NASDAQ:AERI opened at $49.95 on Tuesday. Aerie Pharmaceuticals has a 12-month low of $38.22 and a 12-month high of $66.60. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -14.82 and a beta of 0.96. The company has a debt-to-equity ratio of 0.91, a current ratio of 10.09 and a quick ratio of 10.09.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.04. sell-side analysts anticipate that Aerie Pharmaceuticals will post -3.62 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Bamco Inc. NY raised its stake in shares of Aerie Pharmaceuticals by 19.4% during the 4th quarter. Bamco Inc. NY now owns 7,351 shares of the company’s stock worth $439,000 after buying an additional 1,195 shares during the period. Teachers Retirement System of The State of Kentucky raised its stake in shares of Aerie Pharmaceuticals by 2.1% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 62,720 shares of the company’s stock worth $3,748,000 after buying an additional 1,273 shares during the period. Swiss National Bank raised its stake in shares of Aerie Pharmaceuticals by 2.5% during the 1st quarter. Swiss National Bank now owns 53,900 shares of the company’s stock worth $2,924,000 after buying an additional 1,300 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Aerie Pharmaceuticals by 1.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 108,311 shares of the company’s stock worth $5,876,000 after buying an additional 1,411 shares during the period. Finally, QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth approximately $125,000. 97.32% of the stock is owned by institutional investors and hedge funds.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $86.00 Price Target

Aerie Pharmaceuticals (NASDAQ:AERI) has been given a $86.00 price target by stock analysts at Canaccord Genuity in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 72.17% from the company’s current price.

AERI has been the subject of a number of other reports. Zacks Investment Research raised Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, January 22nd. Seaport Global Securities initiated coverage on Aerie Pharmaceuticals in a report on Friday, January 26th. They issued a “buy” rating and a $78.00 price target for the company. BidaskClub raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Mizuho reissued a “buy” rating and issued a $87.00 price target on shares of Aerie Pharmaceuticals in a report on Monday, January 29th. Finally, HC Wainwright assumed coverage on Aerie Pharmaceuticals in a report on Friday, February 16th. They issued a “buy” rating and a $78.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $77.92.

Get Aerie Pharmaceuticals alerts:

Shares of NASDAQ:AERI opened at $49.95 on Tuesday. Aerie Pharmaceuticals has a 12-month low of $38.22 and a 12-month high of $66.60. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -14.82 and a beta of 0.96. The company has a debt-to-equity ratio of 0.91, a current ratio of 10.09 and a quick ratio of 10.09.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.04. sell-side analysts anticipate that Aerie Pharmaceuticals will post -3.62 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Bamco Inc. NY raised its stake in shares of Aerie Pharmaceuticals by 19.4% during the 4th quarter. Bamco Inc. NY now owns 7,351 shares of the company’s stock worth $439,000 after buying an additional 1,195 shares during the period. Teachers Retirement System of The State of Kentucky raised its stake in shares of Aerie Pharmaceuticals by 2.1% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 62,720 shares of the company’s stock worth $3,748,000 after buying an additional 1,273 shares during the period. Swiss National Bank raised its stake in shares of Aerie Pharmaceuticals by 2.5% during the 1st quarter. Swiss National Bank now owns 53,900 shares of the company’s stock worth $2,924,000 after buying an additional 1,300 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Aerie Pharmaceuticals by 1.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 108,311 shares of the company’s stock worth $5,876,000 after buying an additional 1,411 shares during the period. Finally, QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth approximately $125,000. 97.32% of the stock is owned by institutional investors and hedge funds.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)